International Journal of Clinical Pharmacy

, Volume 33, Issue 6, pp 882–885 | Cite as

Medication management during pregnancy: role of the pharmacist

  • Nardin Samuel
  • Adrienne EinarsonEmail author


A community pharmacist is frequently the first healthcare professional who is asked to give advice regarding medication use during pregnancy. As 50% of pregnancies are unplanned, a woman often discovers she is pregnant while already taking a medication and visits a pharmacy which is easily accessible, to enquire if she has harmed her baby by this action. Following a review of the literature, of which there is a paucity on this topic, we found that pharmacists often do not feel equipped to dispense teratology information and frequently refer the woman to her attending physician, without giving any information. In addition, it was clear that even when they did give information, it was not necessarily evidence-based and at times, inaccurate and based on their own opinions. In this article, we have attempted to make pharmacists aware of all the sources that are available, to enable them to perform this important role as a member of the health care team. These include websites, texts, evidence-based literature, teratogen information services and more. With the knowledge extracted from various resources, following critical appraisal of the data, they should be more comfortable and feel better equipped to transfer this information to a pregnant woman. In conclusion, while there may be a lack of adequate information regarding use of certain medications during pregnancy, pharmacists should be able to integrate available information with their medication expertise, to make appropriate individual risk/benefit decisions. This requires active engagement with pregnant women, rather than automatically referring them to their physician, thus establishing the pharmacist role as an essential member of the health care team.


Evidence-based information Medications Pregnancy Pharmacist Resources 




Conflicts of interest

None declared.


  1. 1.
    Nordeng H, Ystrøm E, Einarson A. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol. 2010;66:207–14.PubMedCrossRefGoogle Scholar
  2. 2.
    Bradley CP. The future role of pharmacists in primary care. Br J Gen Pract. 2009;59(569):891–2.PubMedCrossRefGoogle Scholar
  3. 3.
    Lyszkiewicz D, Gerichhausen S, Björnsdóttir I, Einarson TR, Koren G, Einarson A. Evidencebased information on drug use during pregnancy: a survey of community pharmacists in three countries. Pharm World Sci. 2001;23:76–81.PubMedCrossRefGoogle Scholar
  4. 4.
    Einarson A, Mazzieri MR, Sola NH, Einarson TR, The Cordoba Pharmacy Practice Research Group. Evidence based information on drug use during pregnancy: assessment of community pharmacists in Cordoba, Argentina. Pharmaceutical Care (España). 2002;4:209–21.Google Scholar
  5. 5.
    Vanham D, Spinewine A. Evaluation of the quality of counselling provided by community pharmacists to pregnant women. J Pharm Belg 2010; (3):68–74.Google Scholar
  6. 6.
    Damase-Michel C, Vie C, Lacroix I, Lapeyre-Mestre M, Montastruc JL. Drug counselling in pregnancy: an opinion survey of French community pharmacists. Pharmacoepidemiol Drug Safety. 2004;13:711–5.CrossRefGoogle Scholar
  7. 7.
    Cohen LS, Wang B, Nonacs R, Viguera AC, Lemon EL, Freeman MP. Treatment of mood disorders during pregnancy, postpartum. Psychiatr Clin North Am. 2010;33(2):273–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Damase-Michel C, Christaud J, Berrebi A, Lacroix I, Montastruc JL. What do pregnant women know about non-steroidal anti-inflammatory drugs? Pharmacoepidemiol Drug Safety. 2009;18:1034–8.CrossRefGoogle Scholar
  9. 9.
    Jentink J, Dolk H, Loane MA, Morris JK, Wellesley D, Garne E, de Jong-van den Berg L; EUROCAT Antiepileptic Study Working Group. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ. 2010; 341:c6581. doi: 10.1136/bmj.c6581. Review.
  10. 10.
    Czeizel EA, Rockenbauer M, Sorensen HT, Olsen J. Nitrofurantoin and congenital abnormalities. Eur J Obstet Gynecol Reprod Biol. 2001;95:119–26.PubMedCrossRefGoogle Scholar
  11. 11.
    Ben David S, Einarson T, Ben David Y, Nulman I, Pastuszak A, Koren G. The safety of nitrofurantoin during the first trimester of pregnancy: meta-analysis. Fundam Clin Pharmacol. 1995;9:503–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Gait JE. Hemolytic reactions to nitrofurnatoin in patients with glucose-6-phasephate dehydrogenase deficiency: theory and practice. DICP Ann Pharmacother. 1990;24:1210–3.Google Scholar
  13. 13.
    Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006;38(2):90–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Canadian Institutes of Health Research [Internet] CIHR. Available from: Cited Apr 5 2011
  15. 15.
    [No authors listed]. Pregnancy labeling. FDA Drug Bull. 1979; 9(4):23–4.Google Scholar
  16. 16.
    Feibus KB. FDA’s proposed rule for pregnancy and lactation labelling: improving maternal child health through well-informed medicine use. J Med Toxicol. 2008;4(4):284–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Einarson A. Antidepressants and pregnancy: complexities of producing evidence-based information. CMAJ. 2010;182(10):1017–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Otis Pregnancy [Internet]. Available from: (2010). Cited Apr 6 2011
  19. 19.
    Entis Org [Internet]. Available from: Cited Apr 6 2011
  20. 20.
    Briggs CG. Drugs in pregnancy and lactation. 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.Google Scholar
  21. 21.
    National Library of Medicine’s TOXNET system [Internet]. Available from: Cited Apr 6 2011
  22. 22.
    American Hospital Formulary Service [Internet]. Available from: Cited Apr 6 2011
  23. 23.
    Reproductive Toxicology Center [Internet]. Available from: (2011). Cited Apr 6 2011

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.The Motherisk ProgramThe Hospital for Sick ChildrenTorontoCanada

Personalised recommendations